Psilocin Salt Crystal Forms for Stability and Solubility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Psilocin's poor crystallinity, limited bulk purity upon crystallization, susceptibility to auto-catalyzed oxidation, and low water solubility hinder its therapeutic applications due to stability and handling issues.
Innovation Solution
Development of pharmaceutically acceptable salts such as 1:1 benzoate, 1:1 tartrate, 2:1 succinate, and 2:1 or 1:1 1,5-naphthalenedisulfonic acid salts of psilocin, along with specific crystal forms, to enhance stability and solubility.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If psilocin is used in its free base form, then it can be handled and stored, but it exhibits poor crystallinity, limited bulk purity upon crystallization, susceptibility to auto-catalyzed oxidation, and low water solubility
Solution Approach 1:
The patent applies parameter changes by converting psilocin from its free base form to salt forms with different counterions (benzoate, tartrate, succinate, 1,5-naphthalenedisulfonate). This chemical parameter change fundamentally alters the physical properties including crystallinity, solubility, and stability, resolving the contradiction between manufacturability and reliability
Solution Approach 2:
The invention creates composite materials by combining psilocin with various counterions to form salt complexes. These composite salt forms integrate the benefits of improved crystallinity and stability while maintaining the therapeutic activity of psilocin, effectively addressing both the manufacturability and reliability concerns
2Manufacturing precision
If psilocin is crystallized to improve purity, then bulk purity is enhanced, but crystallinity remains poor and handling characteristics are not significantly improved
Solution Approach 1:
By changing the chemical form from free base to salt, the patent achieves both improved crystallinity and enhanced bulk purity simultaneously. The salt formation process creates well-defined crystal structures with characteristic XRPD patterns, resolving the contradiction between manufacturing precision and physical form
3Duration of action of moving object
If psilocin is stored for prolonged periods, then therapeutic applications can be pursued, but auto-catalyzed oxidation occurs
Solution Approach 1:
The patent converts the harmful oxidation issue into a benefit by forming salt forms that are inherently more stable toward oxidation. The salt structures protect the psilocin molecule from auto-catalyzed oxidation, enabling prolonged storage while maintaining therapeutic integrity
Solution Approach 2:
The salt forms create a more chemically inert environment for the psilocin molecule, reducing its susceptibility to oxidation. This effectively creates an protected state that allows for long-term storage without degradation, addressing the contradiction between storage duration and oxidation resistance
4Ease of operation
If psilocin is used as free base, then it can be administered, but water solubility is low limiting therapeutic delivery
Solution Approach 1:
The patent applies parameter changes by selecting counterions that enhance water solubility while maintaining pharmacological activity. The charged nature of the salt forms improves aqueous solubility compared to the free base, facilitating better therapeutic delivery and administration
Data Source
AI summary
The present invention composition features pharmaceutically acceptable salts of psilocin and compositions thereof. The pharmaceutically acceptable salts of psilocin may be used to treat a disease or condition, such as a neurological injury, an inflammatory condition, chronic pain, or a psychological condition, in a subject in need thereof.